Reports Q3 revenue $17.6B, consensus $16.07B. “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio,” said David Ricks, Lilly chair and CEO. “We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved U.S. FDA approval of Inluriyo (imlunestrant)-marking key progress across our pipeline. We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA moves to accelerate biosimilar development, lower drug costs
- These Are the Stocks Reporting Earnings Today – October 30, 2025
- Notable companies reporting before tomorrow’s open
- Eli Lilly (LLY) Invests $1.2 Billion in Puerto Rico Manufacturing Plant
- AI Daily: Nvidia becomes first $5 trillion company as AI boom powers rally